Vivani Medical (NASDAQ:VANI) Insider Donald Dwyer Buys 20,000 Shares of Stock

Posted by Donna Armstrong on Nov 15th, 2026

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) insider Donald Dwyer acquired 20,000 shares of the stock in a transaction that occurred on Thursday, November 12th. The stock was purchased at an average price of $0.98 per share, for a total transaction of $19,600.00. Following the completion of the acquisition, the insider owned 75,000 shares in the company, valued at $73,500. The trade was a 36.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Vivani Medical Trading Up 2.7%

NASDAQ:VANI traded up $0.03 during trading hours on Friday, hitting $1.01. 368,707 shares of the stock were exchanged, compared to its average volume of 256,490. The firm’s fifty day moving average price is $1.18 and its 200 day moving average price is $1.24. Vivani Medical, Inc. has a 52-week low of $0.80 and a 52-week high of $1.66. The company has a market cap of $91.10 million, a P/E ratio of -3.16 and a beta of 2.51.

Vivani Medical (NASDAQ:VANI – Get Free Report) last released its earnings results on Wednesday, November 11th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on VANI shares. Wall Street Zen lowered Vivani Medical from a “hold” rating to a “sell” rating in a report on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vivani Medical has an average rating of “Hold” and a consensus target price of $3.75.

Read Our Latest Analysis on Vivani Medical

Vivani Medical Company Profile

(Get Free Report)

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.